<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Monogenic hypertension genes</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Monogenic hypertension genes</h1>
<div class="graphic"><div class="figure"><div class="ttl">Monogenic hypertension genes</div><div class="cntnt"><table cellspacing="0"><colgroup width="22%"></colgroup><colgroup width="10%"></colgroup><colgroup span="3" width="22%"></colgroup> <tbody> <tr> <td class="subtitle1">Gene(s)</td> <td class="subtitle1">Chromosome position</td> <td class="subtitle1">Disease name and MIM identifier</td> <td class="subtitle1">Key features of clinical syndrome (other than hypertension)</td> <td class="subtitle1">Mode of inheritance and genetic mechanism</td> </tr> <tr class="divider_bottom"> <td><em>CACNA1H</em><br/> (calcium voltage-gated channel subunit alpha1 H gene)</td> <td>16p</td> <td> <p>Familial hyperaldosteronism type IV</p> MIM 607904</td> <td>Hypokalemia</td> <td>AD; GOF</td> </tr> <tr class="divider_bottom"> <td><em>CLCN2</em><br/> (chloride voltage-gated channel 2 gene)</td> <td>3q</td> <td> <p>Familial hyperaldosteronism type II</p> MIM 605635</td> <td>Hypokalemia</td> <td>AD; GOF</td> </tr> <tr class="divider_bottom"> <td><em>CUL3</em><br/> (cullin 3 gene)</td> <td>2q</td> <td> <p>Pseudohypoaldosteronism type 2 (PHA2; Gordon syndrome)</p> PHA2E MIM 614496</td> <td>Hyperkalemia, response to thiazides</td> <td>AD; LOF</td> </tr> <tr class="divider_bottom"> <td><em>CYP11B1</em><br/> (<a href="https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2591" target="_blank">cytochrome P450 family 11 subfamily B member 1</a> gene)</td> <td>8q</td> <td> <p>CAH due to 11-beta-hydroxylase deficiency (CAH type IV)</p> MIM 202010</td> <td>Hypokalemia, virilization (variable); two-thirds of patients have severe "classic form" with hypertension in first years of life</td> <td>AR; LOF</td> </tr> <tr class="divider_bottom"> <td><em>CYP11B2</em><br/> (<a href="https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2592" target="_blank">cytochrome P450 family 11 subfamily B member 2</a> gene)</td> <td>8p</td> <td> <p>Familial hyperaldosteronism type I (glucocorticoid-remediable aldosteronism)</p> MIM 103900</td> <td>Low plasma renin, increased aldosterone, response to dexamethasone; high genetic heterogeneity and potassium level often normal; high prevalence of intracranial aneurysms</td> <td>AD; GOF; gene expressed under ACTH control (fusion of the promoter region of the gene for <em>CYP11B1</em> and the coding sequences of <em>CYP11B2</em>)</td> </tr> <tr class="divider_bottom"> <td><em>CYP17A1</em><br/> (<a href="https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2593" target="_blank">cytochrome P450 family 17 subfamily A member 1</a> gene)</td> <td>10q</td> <td> <p>CAH due to 17-alpha-hydroxylase deficiency (CAH type V)</p> MIM 202110</td> <td>Hypokalemia, hypogonadism/androgen deficiency</td> <td>AR; LOF</td> </tr> <tr class="divider_bottom"> <td><em>HSD11B2</em><br/> (<a href="https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5209" target="_blank">hydroxysteroid 11-beta dehydrogenase 2</a> gene)</td> <td>16q</td> <td> <p>Cortisol 11-beta-ketoreductase deficiency (syndrome of apparent mineralocorticoid excess)</p> MIM 218030</td> <td>Hypokalemia, low plasma renin, response to spironolactone</td> <td>AR; LOF</td> </tr> <tr class="divider_bottom"> <td><em>KCNJ5</em><br/> (<a href="https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6266" target="_blank">potassium inwardly rectifying channel subfamily J member 5</a> gene)</td> <td>11q</td> <td> <p>Familial hyperaldosteronism type III</p> MIM 613677</td> <td>Hypokalemia, high aldosterone, high 18-oxocortisol and 18-hydroxycortisol</td> <td>AD; LOF</td> </tr> <tr class="divider_bottom"> <td><em>KLHL3</em><br/> (<a href="https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6354" target="_blank">kelch like family member 3</a> gene)</td> <td>5q</td> <td> <p>Pseudohypoaldosteronism type 2 (PHA2; Gordon syndrome)</p> PHA2D MIM 614495</td> <td>Hyperkalemia, response to thiazides</td> <td>AD or AR; LOF (inhibition of <em>KLHL3</em> increases the activity of <em>SLC12A3</em>)</td> </tr> <tr class="divider_bottom"> <td><em>NR3C2</em><br/> (<a href="https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7979" target="_blank">nuclear receptor subfamily 3 group C member 2</a> gene)</td> <td>4q</td> <td> <p>Early-onset AD hypertension with exacerbation in pregnancy (Geller syndrome)</p> MIM 605115</td> <td>Severe hypertension in pregnancy</td> <td>AD; GOF</td> </tr> <tr class="divider_bottom"> <td><em>PDE3A</em><br/> (phosphodiesterase 3A gene)</td> <td>12p</td> <td> <p>AD hypertension with brachydactyly</p> MIM 123805</td> <td>Brachydactyly</td> <td>AD; GOF</td> </tr> <tr class="divider_bottom"> <td><em>SCNN1B</em>, <em>SCNN1G</em><br/> (<a href="https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10600" target="_blank">sodium channel epithelial 1 subunit beta</a> and gamma genes)</td> <td>16p</td> <td> <p>Liddle's syndrome (pseudoaldosteronism)</p> MIM 177200</td> <td>Hypokalemia, metabolic alkalosis, low plasma renin, low aldosterone, response to amiloride</td> <td>AD; GOF</td> </tr> <tr class="divider_bottom"> <td><em>WNK1</em><br/> (<a href="https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:14540" target="_blank">WNK lysine deficient protein kinase 1</a> gene)</td> <td>12p</td> <td> <p>Pseudohypoaldosteronism type 2 (PHA2; Gordon syndrome)</p> PHA2C MIM 614492</td> <td>Hyperkalemia, response to thiazides</td> <td>AR; GOF</td> </tr> <tr> <td><em>WNK4</em><br/> (WNK lysine deficient protein kinase 4 gene)</td> <td>12p</td> <td> <p>Pseudohypoaldosteronism type 2 (PHA2; Gordon syndrome)</p> PHA2B MIM 614491</td> <td>Hyperkalemia, response to thiazides</td> <td>AR; LOF; Â± expression of the thiazide-sensitive Na-Cl co-transporter <em>SLC12A3</em> (NCCT)</td> </tr> </tbody></table></div><div class="graphic_lgnd">For each gene in which variants can induce monogenic hypertension syndromes, the gene name (abbreviation and full name), the physical position, the disease name, and key clinical and genetic features are shown.</div><div class="graphic_footnotes">MIM: Mendelian inheritance in man; AD: autosomal dominant; GOF: gain of function; ACTH: adrenocorticotropic hormone; CAH: congenital adrenal hyperplasia; AR: autosomal recessive; LOF: loss of function.</div><div class="graphic_reference">Adapted from: Ehret GB, Caulfield MJ. Genes for blood pressure: An opportunity to understand hypertension. Eur Heart J 2013; 34:951.</div><div id="graphicVersion">Graphic 105744 Version 3.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
